RESUMO
A partially-blind, three-way crossover study was carried out in 24 patients suffering from chronic urticaria to compare the efficacy and tolerance of brompheniramine maleate with that of clemastine fumarate. Patients received 4-week courses of treatment with 1 tablet twice daily of either 12 mg brompheniramine, 1 mg clemastine or placebo, in random order. Assessments were made by the physician of the patients' condition on entry and of response to treatment at the end of each 2-week period throughout the 12-week study period. At the end of the trial, patients were asked to state their preference, if any, for the different treatments. The results showed that both antihistamines were significantly effective compared to placebo and that at the dosage used brompheniramine was considered significantly better than clemastine in long-term control. Drowsiness was experienced by 4 patients whilst taking brompheniramine compared to 3 patients whilst taking clemastine. One patient experienced anorexia and vomiting with brompheniramine and 4 patients developed gastro-intestinal upsets whilst taking the placebo.
Assuntos
Bromofeniramina/uso terapêutico , Clemastina/uso terapêutico , Piridinas/uso terapêutico , Pirrolidinas/uso terapêutico , Urticária/tratamento farmacológico , Adolescente , Adulto , Idoso , Bromofeniramina/administração & dosagem , Doença Crônica , Clemastina/administração & dosagem , Ensaios Clínicos como Assunto , Preparações de Ação Retardada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Distribuição AleatóriaAssuntos
Bromofeniramina/uso terapêutico , Ciproeptadina/análogos & derivados , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Piridinas/uso terapêutico , Urticária/tratamento farmacológico , Adulto , Doença Crônica , Ensaios Clínicos como Assunto , Ciproeptadina/uso terapêutico , Feminino , Humanos , MasculinoRESUMO
Renal concentrating ability was measured in two groups of arthritic patients. The first had received long-term therapy with azapropazone and the second with other nonsteroidal anti-inflammatory drugs. Even after long periods of treatment, azapropazone did not adversely affect renal concentrating ability.
Assuntos
Apazona/farmacologia , Artrite/tratamento farmacológico , Capacidade de Concentração Renal/efeitos dos fármacos , Triazinas/farmacologia , Adulto , Idoso , Avaliação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Apazona/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Indometacina/uso terapêutico , Triazinas/uso terapêutico , Acetaminofen/uso terapêutico , Adulto , Idoso , Artrite Reumatoide/fisiopatologia , Ensaios Clínicos como Assunto , Feminino , Mãos/fisiopatologia , Humanos , Articulações/fisiopatologia , Masculino , Pessoa de Meia-Idade , Dor/tratamento farmacológico , PlacebosRESUMO
A double-blind crossover trial was carried out in 15 patients with definite rheumatoid arthritis to compare the effectiveness of 1200 mg azapropazone daily and 750 mg naproxen daily, each drug being given for 2 weeks. Patients also received placebo therapy before and between the two treatment periods. The results of subjective and objective assessments showed that both drugs were significantly superior to placebo, but no significant difference could be demonstrated between the two drugs.
Assuntos
Apazona/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Ácidos Naftalenoacéticos/uso terapêutico , Naproxeno/uso terapêutico , Triazinas/uso terapêutico , Adolescente , Adulto , Idoso , Ensaios Clínicos como Assunto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , PlacebosRESUMO
A double-blind trial of azapropazone (300 mg. 4-times daily) and ketoprofen (50 mg. 4-times daily) was carried out in 50 patients with acute backache sufficiently severe to necessitate hospital admission. Of 39 patients who completed the full 3-weeks' study period, 18 preferred azapropazone therapy, 10 preferred ketoprofen, and 11 showed either preference for the intermediate placebo period or no preference at all. Ten patients suffered from sufficiently severe side-effects with ketoprofen to necessitate their withdrawal from the trial. There were no similar episodes of withdrawal occurring during the azapropazone period.